With 40 percent of critically ill sepsis patients developing acute kidney injury (AKI), sepsis treatment management becomes a balancing act between competing risks. Delays in proper antibiotic treatment for sepsis can decrease patient survival rates, but an overexposure to antimicrobials leads to nephrotoxic effects. Assessing biomarkers early and often through the use of diagnostics supports clinicians and pharmacists as they combat bacterial infections while reducing the risk for AKI.

Louis Guzzi, MD, FCCM, Director of Critical Care Medicine at AdventHealth Medical Group

Sepsis Alliance
September 14, 2021